# **Special Issue**

# Peptide Therapeutics 2.0

### Message from the Guest Editor

Interest in peptide drug discovery is continuously growing in the pharmaceutical industry; thus, the number of therapeutic peptides evaluated in clinical trials is increasing. As a result, year on year, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several of these chemical entities as new drugs. As well as being present in new drugs as active pharmaceutical ingredients (APIs), peptides are also used as shuttles to address other drugs to a specific cell or as linkers, for instance, in antibody–drug conjugates (ADCs). This Special Issue of *Molecules*, Peptide Therapeutics 2.0, aims to highlight the newest discoveries related to peptides as therapeutic agents.

### **Guest Editor**

Prof. Dr. Beatriz G. De la Torre

School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4001, South Africa

### Deadline for manuscript submissions

closed (31 May 2022)



# **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/47839

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





## **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

### **Journal Rank:**

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

